ClinicalTrials.gg
Enrolling by invitationNCT06162494Updated Mar 27, 2026

Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients

A Phase 4 interventional study of Recombinant Zoster Vaccine in Varicella Zoster, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago. Enrolling by invitation at 3 sites in United States. Open to participants aged 19 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Ann & Robert H Lurie Children's Hospital of Chicago · Phase 4, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
19 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 44 studies in Chickenpox with a site in United States — 7 open to participants now, 9 under way, 5 of them phase 3. Chickenpox · United States.

Planned enrollment
29th of 39
80 · median 400
Started
2024
with 2 others
Phase 4
3 of 44
1 open now
Registered
38th of 44
by date
Lead sponsor
1 of 44
Ann & Robert H Lurie Children's Hospital of Chicago

Among the 44 studies in Chickenpox with a site in United States, this one is the 29th largest by planned enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2024, is one of 3 in phase 4, and was the 38th registered.

Chickenpox

180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.

Browse Chickenpox studies →

Open to participants now

7 of the 44 studies in Chickenpox with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Chickenpox studies recruiting now, 3 (19%) set no upper age limit and 13 (81%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.

This study: 19 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Chickenpox with a site in United States, or all of them as a file.
02

Study summary

This goal of this study is to assess the safety and immunogenicity of recombinant zoster virus in young adult solid organ transplant recipients. In this study, participants will receive the recombinant zoster vaccine. They will be monitored for adverse events and tested for antibody and cellular immunity.

Read the detailed description

This is an open-label, non-blinded study to assess the safety and immunogenicity of the Recombinant Zoster Vaccine (RZV) in young adult recipients of solid organ transplants (heart, liver, kidney). After obtaining consent, the patient will have pre-vaccine baseline Varicella Zoster Virus (VZV) anti-gE antibody testing performed by the Weinberg lab and then will be given first dose of vaccine. Participants will be brought back 30-60 days post-vaccine for follow up testing and second dose of vaccine. Participants will then be brought in for follow-up testing at 1-2 months, 6 months, and 12-15 months after receiving 2nd dose of vaccine. Testing for both antibody and cellular immunity to VZV will be performed throughout the study. Telephone, electronic and in-person follow up will be conducted to assess for any clinical signs of VZV reactivation, any vaccine-related side effects or any signs of acute rejection.

03

Conditions studied

  • Varicella Zoster

Keywords

  • Solid Organ Transplant
  • Vaccine
04

Who can participate

Ages eligible
19 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 19 years of age or older and willing to provide written for the study participation.
  • Prior recipient of solid organ transplant more than one year prior to participation.
  • Stable medication regimen for last 6 months prior to participation
  • Participant must have a working telephone number, email address or patient Electronic Health Record (EHR) portal access and be willing to be contacted for study follow-up by any of these means.
  • For participants of , use of effective pregnancy prevention till 2 months post last dose.

Exclusion criteria

Exclusion Criteria:

  • Active treatment with or other agents for acute or chronic rejection.
  • More than 2 courses of treatment for acute rejection within last 2 years prior to study enrollment
  • History of anaphylaxis or other allergic reaction after receiving prior vaccinations or vaccine components
  • Receipt of any inactivated vaccine 8 days before/after dose #1, subunit vaccine 14 days before/after dose #1 and live, attenuated or mRNA vaccine 30 days before/after dose #1
  • History of herpes zoster, primary varicella or VZV vaccination within past 1 year prior to study entry
  • Active pregnancy as defined by positive pregnancy test at the time of screening and prior to each dose of vaccine
  • Febrile illness with Temp ≥39°C and/or infection that require hospitalization or oral antibiotics/antivirals/antifungal/anti-parasite medication within 14 days prior to day 1.
  • Any condition that, in the opinion of the investigator, may interfere with optimal participation in the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Recombinant Zoster Vaccine Administration and Testing

    all participants will receive 2 doses of recombinant zoster vaccine (Shingrix)

    Biological: Recombinant Zoster Vaccine

Interventions

  • BiologicalShingrixStudies of ShingrixShingrix pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    After giving consent, participants will be given first dose of vaccine. Participants will be brought back 60-90 days post-vaccine for follow up testing and second dose of vaccine

    Also known as: Shingrix

06

What researchers measure

Primary outcomes

  1. Adverse Event Reporting

    Percentage of vaccinees with any adverse event (AE) reported as well as those related to receipt of each dose of a 2-dose series of Recombinant Zoster Vaccine (RZV), to be analyzed within the following categories 1. Adverse Events of Special Interests (AESI) including local reactions, clinically diagnosed rejection, or varicella disease through the end of the study period (one year post dose 2) 2. Serious Adverse Events (SAEs) through the end of the study period (one year post dose 2) 3. Potential Immune Mediated Diseases (pIMDs) through the end of the study period (one year post dose 2) 4. Any AE present within 30 days of vaccine administration (dose 1 or dose 2) or pregnancy at any point during the study

    Time frame: 30 days-1 year

  2. Anti-glycoprotein E antibody Concentration

    Percentage of vaccinees with 4-fold rise in anti-glycoprotein E antibody concentration

    Time frame: 30-60 days

Secondary outcomes

  1. Glycoprotein E-Specific Cellular Responses

    Percentage of vaccinees with 2-fold rise in glycoprotein E-specific cellular responses as defined by interferon and IL-2 measured by Fluorospot

    Time frame: 30-60 days

  2. Acute Rejection Reporting

    Percentage of vaccinees that develop complications of acute rejection within 2 months of receiving each dose of the 2-dose series compared to historical time since transplant-graft- and immunosuppressive regimen-matched unvaccinated controls

    Time frame: 2 months

Other outcomes

  1. Exploratory Outcome

    Percentage of vaccinees with 4-fold rise in anti-glycoprotein E antibody concentration within groups 1)previous recipients of varicella vaccine during childhood 2)those with natural infection or 3)those with no history of either natural infection/vaccination at Day 30-60 post-dose 2 Comparison of percentage of participants with 2-fold rise in glycoprotein E-specific cellular responses between those with detectable cellular response pre-vaccine vs. those with no detectable response pre-vaccine at Day 30-60 post-dose 2 Percentage of vaccinees with 4-fold rise in anti-glycoprotein E antibody concentration comparing transplant patients with "high" vs. "low" "level of suppression" (defined as # of immunosuppressive agents and/or serum drug level of immunosuppressive agent) at the time of vaccination at Day 30-60 post-dose 2

    Time frame: 30-60 days

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Mar 2027, 36 months after the start.

Of 14 phase 4 interventional studies under Chickenpox, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 22. This study's planned 36 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2023
First posted
Dec 8, 2023
StartActual
Mar 18, 2024
Primary completionEst.
Mar 31, 2027
CompletionEst.
Sep 30, 2028
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06162494
Collaborators
Children's Hospital Colorado, Children's Hospital Medical Center, Cincinnati
Responsible party
Ravi Jhaveri (Division Head of Pediatric Infectious Diseases, Principal Investigator, Ann & Robert H Lurie Children's Hospital of Chicago) — Principal investigator
First posted
Dec 8, 2023
Start date
Mar 18, 2024
Primary completion
Mar 31, 2027 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Mar 27, 2026

Study contacts

Ravi Jhaveri, MD
principal investigator · Ann and Robert H Lurie Children's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion